Novartis is a global collaborator of choice for biotechnology companies and academic centers seeking to discover and develop drugs for a range of inadequately treated diseases. Through the NIBR Strategic Alliances Group, NIBR has established productive alliances with over 300 collaborators, both academic and industrial.
We continue to look for new ways to combine our own scientific knowledge and expertise with that of the rest of the research community, to find the shortest path to new treatments for disease.
If you have a technology or product that might help in our quest, we want to hear from you.
Our global research efforts begin and end with the patient.